Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

A late-stage trial shows a daily pill helped people lose 12% of their body weight—without injections. Nine teens arrested ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...

Actor Christopher Biggins has revealed he is using weight loss jabs as he needed to lose weight after having surgery on his knee. Porridge star Biggins, 76, said he is taking Mounjaro, which is made ...

The company said Friday that it received FDA approval for a new Wegovy indication as a treatment of a fatty liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH, in adults ...

Novo Nordisk A/S shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...